Table 3. Visual acuity change from baseline at one year by the combination of VEGFR2 SNPs rs4576072 and rs6828477 in CATT and IVAN.
| Ranibizumab and Bevacizumab Combined | Ranibizumab only | |||||
|---|---|---|---|---|---|---|
| rs4576072 | rs4576072 | |||||
| Mean (SD) in CATT | ||||||
| rs6828477 | TT | CT | CC | TT | CT | CC |
| TT | 9.3 (14.2) | 9.1 (12.6) | -- | 10.9 (10.9) | 9.5 (12.2) | -- |
| CT | 7.8 (14.5) | 8.1 (13.8) | 5.8 (12.0) | 8.5 (12.9) | 11.1 (11.6) | 5.3 (13.4) |
| CC | 7.5 (14.9) | 7.7 (15.0) | -- | 5.4 (14.8) | 5.7 (16.5) | -- |
| P=0.64 | P=0.21 | |||||
| Mean (SD) in IVAN | ||||||
| rs6828477 | TT | CT | CC | TT | CT | CC |
| TT | 5.3 (11.2) | 3.7 (13.2) | 10.4 (22.4) | 5.0 (10.9) | 4.8 (15.8) | -- |
| CT | 7.0 (12.3) | 5.2 (10.6) | 6.9 (14.4) | 6.6 (11.6) | 6.6 (11.4) | 6.5 (5.2) |
| CC | 5.1 (12.5) | 2.3 (9.0) | 5.7 (22.5) | 8.3 (13.9) | 4.4 (4.1) | -- |
| P=0.73 | P=0.87 | |||||
SD = Standard deviation.
CATT = Comparison of AMD Treatments Trials.
IVAN = Alternative Treatments to Inhibit VEGF in Patients with Age-Related Choroidal Neovascularization.
--: Mean (SD) was not calculated due to because the number of patients is less than 5.